CHD4 antibody

Name: CHD4 antibody
SKU: GTX124186_G10
Availability: BackOrder

GTX124186

ApplicationsImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Product group Antibodies

ReactivityHuman, Mouse

TargetCHD4

Overview

Supplier
GeneTex
Product Name
CHD4 antibody
Delivery Days Customer
9
Application Supplier Note
WB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
Applications
ImmunoFluorescence, ImmunoPrecipitation, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Certification
Research Use Only
Clonality
Polyclonal
Concentration
1 mg/ml
Conjugate
Unconjugated
Gene ID1108
Target name
CHD4
Target description
chromodomain helicase DNA binding protein 4
Target synonyms
CHD-4, Mi-2b, Mi2-BETA, SIHIWES, chromodomain-helicase-DNA-binding protein 4, ATP-dependent helicase CHD4, Mi-2 autoantigen 218 kDa protein
Host
Rabbit
Isotype
IgG
Protein IDQ14839
Protein Name
Chromodomain-helicase-DNA-binding protein 4
Scientific Description
The product of this gene belongs to the SNF2/RAD54 helicase family. It represents the main component of the nucleosome remodeling and deacetylase complex and plays an important role in epigenetic transcriptional repression. Patients with dermatomyositis develop antibodies against this protein. [provided by RefSeq]
Reactivity
Human, Mouse
Storage Instruction
-20°C or -80°C,2°C to 8°C
UNSPSC
12352203

Chang CL, Huang CR, Chang SJ, et al. CHD4 as an important mediator in regulating the malignant behaviors of colorectal cancer. Int J Biol Sci. 2021,17(7):1660-1670. doi: 10.7150/ijbs.56976
Read this paper
Ou-Yang F, Pan MR, Chang SJ, et al. Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics. Life Sci. 2019,238:116963. doi: 10.1016/j.lfs.2019.116963
Read this paper
Wang HC, Chou CL, Yang CC, et al. Over-Expression of CHD4 Is an Independent Biomarker of Poor Prognosis in Patients with Rectal Cancers Receiving Concurrent Chemoradiotherapy. Int J Mol Sci. 2019,20(17). doi: 10.3390/ijms20174087
Read this paper
Luo CW, Wu CC, Chang SJ, et al. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells. Exp Cell Res. 2018,363(1):65-72. doi: 10.1016/j.yexcr.2017.12.032
Read this paper
Hou MF, Luo CW, Chang TM, et al. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer. Exp Cell Res. 2017,359(2):458-465. doi: 10.1016/j.yexcr.2017.08.029
Read this paper
Yeo AJ, Becherel OJ, Luff JE, et al. Senataxin controls meiotic silencing through ATR activation and chromatin remodeling. Cell Discov. 2015,1:15025. doi: 10.1038/celldisc.2015.25
Read this paper